Zobrazeno 1 - 10
of 94
pro vyhledávání: '"Hiroko Nishida"'
Publikováno v:
HemaSphere, Vol 7, p e5865466 (2023)
Externí odkaz:
https://doaj.org/article/db8d7ce12f514bbc9cd9d91440c29b80
Publikováno v:
Leukemia Research Reports, Vol 10, Iss , Pp 11-15 (2018)
Secondary bone marrow involvement of non-Hodgkin's lymphoma (NHL) is relatively common. However, primary isolated bone marrow involvement in NHL which was successfully treated and remains in complete remission (CR) for a long-term duration without an
Externí odkaz:
https://doaj.org/article/dc33bb712e344121a2c98b6052b3ec5c
Autor:
Hiroko Nishida
Publikováno v:
Hematology Reports, Vol 10, Iss 1 (2018)
Osteolytic bone disease, characterizedby bone pain, increased risk of pathologicfractures, tumor-induced hypercalcemiaknown as skeletal-related events (SREs), isa frequent complication of patients withmultiple myeloma (MM) and persists evenin the abs
Externí odkaz:
https://doaj.org/article/77795894e5ef4a0983535216eae40a05
Autor:
Kohji Yamada, Mutsumi Hayashi, Hiroko Madokoro, Hiroko Nishida, Wenlin Du, Kei Ohnuma, Michiie Sakamoto, Chikao Morimoto, Taketo Yamada
Publikováno v:
PLoS ONE, Vol 8, Iss 4, p e62304 (2013)
CD26 is a type II glycoprotein known as dipeptidyl peptidase IV and has been identified as one of the cell surface markers associated with various types of cancers and a subset of cancer stem cells. Recent studies have suggested that CD26 expression
Externí odkaz:
https://doaj.org/article/7094d3960ea74e23a3ca290d9987167f
Autor:
Hiroko, NISHIDA, Naoto, KUGA
Publikováno v:
鳴門教育大学学校教育研究紀要 = Bulletin of Center for Collaboration in Community Naruto University of Education. 36:1-10
本研究の目的は，生徒が抱える教育課題解決に向けた組織的な取組を生み出す校内研修システムの開発である。その目的達成のための組織体制として，全教職員による協働で教育意思形
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=jairo_______::107e0cfc1199cb4c647097e47ccc7a3f
http://id.nii.ac.jp/1624/00029338/
http://id.nii.ac.jp/1624/00029338/
Publikováno v:
Blood. 140:3151-3152
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e08cde9af1f85109960fba4885e0dc8c
https://doi.org/10.1182/blood-2022-157672
https://doi.org/10.1182/blood-2022-157672
Agency refers to the capacity to act and act upon, to initiate and carry out actions either for their own sakes or to influence and affect others. The concept is often invoked in music studies, but the nature and types of actions and agents are defin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b6cb1ba88029aae731997f4a6b6965d9
https://doi.org/10.1093/oso/9780198860761.003.0004
https://doi.org/10.1093/oso/9780198860761.003.0004
Autor:
Hiroko Nishida
Publikováno v:
Cancers, Vol 13, Iss 2712, p 2712 (2021)
Cancers
Cancers
Simple Summary Despite rapid advances in the development of novel agents over the last decade for the treatment of multiple myeloma (MM), MM remains an incurable disease. Therefore, the development of novel targeting therapies with different mechanis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9dab1f1f2162954faef92f6ec9a74b4
https://www.mdpi.com/2072-6694/13/11/2712
https://www.mdpi.com/2072-6694/13/11/2712
Publikováno v:
Leukemia Research Reports, Vol 10, Iss, Pp 11-15 (2018)
Leukemia Research Reports
Leukemia Research Reports
Secondary bone marrow involvement of non-Hodgkin's lymphoma (NHL) is relatively common. However, primary isolated bone marrow involvement in NHL which was successfully treated and remains in complete remission (CR) for a long-term duration without an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a3b61e54e7c570b75a623d89b40b32d
https://doi.org/10.1016/j.lrr.2018.05.004
https://doi.org/10.1016/j.lrr.2018.05.004
Autor:
Michiie Sakamoto, Hiroko Madokoro, Hiroko Nishida, Mutsumi Hayashi, Koji Yamada, Hiroshi Yanagawa, Taketo Yamada, Chikao Morimoto
Publikováno v:
Cancers
Cancers, Vol 11, Iss 8, p 1138 (2019)
Volume 11
Issue 8
Cancers, Vol 11, Iss 8, p 1138 (2019)
Volume 11
Issue 8
Here, we report a novel antibody drug conjugate (ADC) with the humanized anti-CD26 monoclonal antibody YS110 and triptolide (TR-1). YS110 has an inhibitory activity against the CD26-positive tumor growth via the immunological and direct pathway, such
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae9f2e1abab41f76f2881e3fddbaf39f
https://pubmed.ncbi.nlm.nih.gov/31398954
https://pubmed.ncbi.nlm.nih.gov/31398954